
According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60 million, a 0.45% change since Q4. In Q4, Neurocrine Biosciences brought in $312.00 million in sales but lost $7.30 million in earnings.